SCHEMBL6340626

SCHEMBL6340626

NC(=O)c1nn(-c2ccc(S(N)(=O)=O)cc2)c2c1ccc1ccc(NC(=O)c3ccccc3Cl)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
PTGS2 P35354 7/20 0.47
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA9 Q16790 4/20 0.46
MAPK9 P45984 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
CA12 O43570 1/20 0.43
CA5A P35218 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
CA4 P22748 1/20 0.43
KDR P35968 1/20 0.43
CA7 P43166 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
MT-CO2 P00403 1/20 0.42
PTGS1 P23219 3/20 0.42
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350930 0.93 KMT2A (0.46) KMT2APTGS2CA1CA2CA9
SCHEMBL6345452 0.92 KMT2A (0.48) KMT2APTGS2CA1CA2CA9
SCHEMBL6354558 0.92 KMT2A (0.44) KMT2APTGS2ALDH1A1POLBJAK2
SCHEMBL6344535 0.90 KMT2A (0.54) KMT2APTGS2CA1CA2CA9
SCHEMBL6343697 0.90 PTGS2 (0.46) KMT2APTGS2CA1CA2CA9
SCHEMBL6342809 0.90 PTGS2 (0.49) PTGS2CA1CA2CA9CA12
SCHEMBL6342695 0.89 IKBKB (0.51) KMT2APTGS2MAPK9ALDH1A1PTGS1
SCHEMBL6343763 0.88 IKBKB (0.49) KMT2AALDH1A1LMNAJAK2JAK1
SCHEMBL6354562 0.87 PTGS2 (0.46) PTGS2CA1CA2CA9CA12
SCHEMBL6342129 0.87 PTGS2 (0.55) KMT2APTGS2CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 KMT2A 2374/4885PTGS2 37/4885CA1 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.